Form 4: Altimmune CSO Scot Roberts Exercises RSUs

Altimmune's Chief Scientific Officer, M. Scot Roberts, reported the exercise of Restricted Stock Units and a subsequent sale of shares to cover tax obligations.

Summary

• M. Scot Roberts, Chief Scientific Officer of Altimmune, Inc., acquired 15,850 shares of common stock on January 27, 2026, through the vesting and exercise of Restricted Stock Units (RSUs).
• The acquisition price for these shares was $0, as they represent the conversion of vested RSUs.
• Following this acquisition, Roberts beneficially owned 100,143 shares of common stock.
• Concurrently, Roberts disposed of 4,748 shares of common stock on January 27, 2026, at a price of $6.18 per share.
• This disposition was solely to cover tax liabilities associated with the vesting of the RSUs.
• After both transactions, Roberts' direct beneficial ownership of Altimmune common stock stands at 95,395 shares.
• Roberts also holds 47,550 Restricted Stock Units, which vest in substantially equal annual installments over four years following January 27, 2025, contingent on continued service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine executive compensation event. The vesting of RSUs and the subsequent tax-related sale are expected, and the executive retains a significant number of shares and unvested units, indicating continued alignment with company performance.

Positives

• The exercise of Restricted Stock Units indicates a vesting event, which is a standard part of executive compensation and retention.
• The net effect of the RSU vesting and tax-related sale is an increase in M. Scot Roberts' direct beneficial ownership of Altimmune common stock by 11,102 shares (15,850 acquired 4,748 disposed) from his holdings prior to the vesting event, demonstrating continued insider equity ownership.
• The remaining 47,550 unvested RSUs indicate a long-term incentive for the Chief Scientific Officer to remain with the company and contribute to its success.

Negatives

• A portion of the vested shares (4,748 shares) was immediately sold to cover tax obligations, which, while a common practice, represents a reduction in direct equity holdings from the peak post-vesting amount.

Future Outlook

The filing indicates that M. Scot Roberts holds 47,550 unvested Restricted Stock Units, which are scheduled to vest in substantially equal annual installments over the next four years following January 27, 2025, contingent on his continued service to Altimmune, Inc. This suggests a long-term retention strategy for a key executive.

Industry Context

StockSavvy.ai notes that the exercise of Restricted Stock Units and subsequent sale for tax purposes is a routine event in executive compensation across the biotechnology and pharmaceutical industries. It reflects the standard practice of equity-based incentives designed to align executive interests with shareholder value over the long term. This particular filing does not provide specific insights into broader industry trends but rather details an individual executive's compensation activity.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of RSU vesting over a multi-year period is a common practice in executive compensation packages within the biotech sector, similar to companies like Moderna or BioNTech, which use equity incentives to retain key scientific talent.
• The immediate sale of shares to cover tax liabilities upon vesting is also a standard and expected event, not indicative of a lack of confidence in the company, but rather a necessary action to manage tax obligations.
• No specific comparable companies or projects are mentioned in the filing to allow for a direct performance comparison.

Stakeholder Impact

• Shareholders: The filing indicates a key executive's continued equity ownership and long-term incentive alignment, which can be viewed positively as it ties management's interests to shareholder value. The sale for tax purposes is a routine event and not a discretionary sale.

Next Steps

• Continued vesting of M. Scot Roberts' remaining 47,550 Restricted Stock Units in substantially equal annual installments over the next four years following January 27, 2025, subject to his continued service.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the vesting of Restricted Stock Units and a subsequent sale of shares to cover tax liabilities. It does not provide new fundamental information about Altimmune's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The executive's continued significant equity holdings and unvested RSUs suggest ongoing alignment with the company's long-term prospects, supporting a 'hold' stance for existing investors.

Keywords

Altimmune, ALT, Form 4, Insider Trading, Restricted Stock Units, RSU, Executive Compensation, Chief Scientific Officer, M. Scot Roberts, Stock Vesting, Equity Holdings